Olympus Partners has acquired PAI Pharma (“PAI”), the leading developer, manufacturer and distributor of generic oral liquids in both ready-to-dose (“RTD”) cups and bottles in the U.S. PAI offers the broadest portfolio of generic oral liquid medicines in the industry, meeting the unique needs of retail chains, independent pharmacies, hospitals, long-term care facilities, and government agencies. The company is headquartered in Parsippany, NJ and operates from two large manufacturing campuses in Greenville, SC.
“PAI has been at the forefront of manufacturing better-targeted suspensions, oral solutions, and liquids across a variety of packaging formats for nearly 50 years” said Griffin Barstis, Partner at Olympus. “We are excited to work with a team with a track record as impressive as PAI as they continue their mission of delivering medications safely, reliably, and affordably.”
Kurt Orlofski, CEO of PAI, added, “The team and I are thrilled to partner with Olympus as we continue our evolution as a company. Given their experience and success, we are certain they will be invaluable partners as we look to accelerate our growth.”
The Olympus team included Griffin Barstis, Jim Conroy, George Swenson, Rabela Bodini, and Lester Coleman. Olympus was represented by Matt Goulding and Matt Dunnet from Kirkland & Ellis.